Phenotypic drug discovery / edited by Beverley Isherwood and Angelique Augustin

Intro -- Half Title -- Title -- Copyright -- Preface -- Foreword Phenotypic Drug Discovery: A Personal Perspective -- Contents -- Chapter 1 Phenotypic Drug Discovery: History, Evolution, Future -- 1.1 Introduction -- 1.2 History -- 1.3 Translational Knowledge Gaps -- 1.4 Formalization of Empiricism into PDD -- 1.5 The Future of PDD -- References -- Chapter 2 Development and Validation of Disease Assays for Phenotypic Screening -- 2.1 Introduction -- 2.2 Assay Design: Connecting to Clinically Relevant Biology -- 2.3 Assay Performance: Planning for Analysis -- 2.4 Triage of Phenotypic Hits.

2.5 Mechanism Classification of Phenotypic Hits -- 2.6 Early Compound De-risking: Human Pharmacology-based Screening Funnel -- 2.7 Challenges and Opportunities: Data Management and Analysis -- 2.8 Summary and Outlook -- Acknowledgements -- References -- Chapter 3 The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening -- 3.1 Introduction -- 3.2 Types of Protein/Protein Affinity Tools for Phenotypic Screening -- 3.3 Application of Protein-based Screening.

3.4 A Case Study Using Secretome-based Screening -- Identification of Potential Paracrine Factors that Stimulate Proliferaiton of Cardiac Cells in the Heart -- 3.5 Summary and Outlook -- Acknowledgements -- References -- Chapter 4 CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening -- 4.1 Introduction -- 4.2 Phenotypic Screening with CRISPR/Cas -- 4.2.1 CRISPR Guides RNA Libraries and Their Design -- 4.2.2 CRISPR-based Screening Strategies for Target Identification -- 4.2.3 Hit Confirmation and Validation -- 4.3 Functional Genomic Big Data Analytics and Artificial Intelligence.

4.4 Summary and Outlook -- References -- Chapter 5 Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation -- 5.1 Introduction -- 5.2 Affinity-based Approaches -- 5.3 Functional Genomics Approaches -- 5.4 Cellular Profiling Approaches -- 5.5 Knowledge-based and Computational Approaches -- 5.6 Discussion and Outlook -- References -- Chapter 6 Artificial Intelligence as an Enabler for Phenotypic Drug Discovery -- 6.1 Introduction -- 6.2 Data-driven Assay Development -- 6.3 Accelerating Hit Discovery with Iterative Machine Learning.

6.4 Increasing the Throughput of Screening and Compound Triage -- 6.4.1 Compound-centric -- 6.4.2 Target-centric -- 6.5 Target Deconvolution and Lead Optimization -- 6.5.1 Identifying PhARTs -- 6.6 Discussion and Outlook -- Abbreviations -- Acknowledgements -- References -- Chapter 7 Public-Private Partnerships to Advance Phenotypic Drug Discovery -- 7.1 Introduction -- 7.2 Collaborate to Advance Knowledge or to Compete? -- 7.3 What Works and What Doesn't in Biomedical PPP? -- 7.4 Rationale for PDD in Industry and Academia -- 7.4.1 The Role of PDD in Industry.

Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of novel medical entities. This book aims to equip researchers with a thought-provoking guide to the application and development of contemporary phenotypic drug discovery for clinical success.

Medienart:	E-Book

Erscheinungsjahr:	[2021] © 2021
Erschienen:	Cambridge: Royal Society of Chemistry ; 2021 © 2021

Reihe:	RSC drug discovery - 77

Sprache:	Englisch

Beteiligte Personen:	Isherwood, Beverley [HerausgeberIn] Augustin, Angelique [HerausgeberIn]

Links:	doi.org [lizenzpflichtig] pubs.rsc.org

ISBN:	978-1-83916-079-0 978-1-83916-072-1

BKL:	44.42 / Pharmazeutische Chemie 58.28 / Pharmazeutische Technologie
Themen:	Arzneimittelforschung Drug development Electronic books Phänotyp

Umfang:	1 Online-Ressource (xxvi, 245 Seiten) ; Illustrationen

doi:	10.1039/9781839160721

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1697642322